Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nucleus Biologics manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This prosecution is being conducted by a lone distinct examiner and is situated within a lone distinct art unit. This suggests a very specific technical focus for the company's current active patent filings. The Biotechnology & Pharmaceuticals focus indicates that the company is likely developing new biological products or pharmaceutical solutions.
The busiest examiner for Nucleus Biologics is SMITH, JENNIFER JOY, who is responsible for 1 busiest examiner pending office action. This accounts for the entirety of the company's pending office actions. For practitioners, this means that the prosecution outcome is highly dependent on this examiner's review. The presence of a lone distinct examiner and a lone distinct art unit indicates that the company's current active intellectual property is focused on a specific area, making the successful resolution of this 1 pending office action a key objective for the company's biotechnology portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SMITH, JENNIFER JOY | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17926546 | MEDIA FORMULATIONS AND PRODUCTION | SMITH, JENNIFER JOY | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17926546 | MEDIA FORMULATIONS AND PRODUCTION | SMITH, JENNIFER JOY | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNucleus Biologics has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer Joy Smith has the most, with 1 of Nucleus Biologics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
